Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas

Kenichi Suda, Masaki Shimoji, Shigeki Shimizu, Katsuaki Sato, Masato Chiba, Kenji Tomizawa, Toshiki Takemoto, Junichi Sou, Tetsuya Mitsudomi

Research output: Contribution to journalArticle

Abstract

Although lung adenocarcinomas (LADs) with ground-glass opacity (GGO; part-solid tumors) have been shown to differ from those without GGO (pure-solid tumors) in clinicopathological features and prognoses, whether programmed death ligand-1 (PD-L1) protein expression differs between these two tumor types is unclear. This study included 124 patients with clinical T1a-c LAD who received pulmonary resections during 2007-2009. The E1L3N antibody was used to stain for PD-L1 in primary LAD specimens. The specimens were considered PD-L1+ if ≥1% of tumor cells showed membrane staining, and were classified as having a high PD-L1+ tumor proportion score (TPS) if ≥50% of the tumor cells did so. Among the 124 patients, 45 had part-solid tumors and 79 had pure-solid tumors. These two groups did not significantly differ in terms of clinical factors. However, the rates for PD-L1 positivity (4% vs. 25%, p < 0.01) and high PD-L1+ TPS (2% vs. 16%, p = 0.02) were significantly higher in the pure-solid tumors. The multivariate analyses (logistic regression model) showed that the odds ratios for PD-L1 positivity and high PD-L1+ TPS in pure-solid LADs were 5.9 (95% CI; 1.2-29.7) and 8.0 (95% CI; 1.0-63.8), respectively. In conclusion, LADs with GGO were correlated with a lower incidence of PD-L1 expression than pure-solid tumors.

Original languageEnglish
JournalBiomolecules
Volume9
Issue number9
DOIs
Publication statusPublished - Sep 7 2019

Fingerprint

Tumors
Ligands
Neoplasms
Adenocarcinoma of lung
Logistic Models
Opacity
Cell membranes
Glass
Logistics
Coloring Agents
Multivariate Analysis
Odds Ratio
Cells
Cell Membrane
Staining and Labeling
Lung
Mortality
Antibodies
Incidence

Keywords

  • biomarkers
  • ground-glass opacity (GGO)
  • lung cancer
  • surgery

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Cite this

Suda, K., Shimoji, M., Shimizu, S., Sato, K., Chiba, M., Tomizawa, K., ... Mitsudomi, T. (2019). Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas. Biomolecules, 9(9). https://doi.org/10.3390/biom9090456

Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas. / Suda, Kenichi; Shimoji, Masaki; Shimizu, Shigeki; Sato, Katsuaki; Chiba, Masato; Tomizawa, Kenji; Takemoto, Toshiki; Sou, Junichi; Mitsudomi, Tetsuya.

In: Biomolecules, Vol. 9, No. 9, 07.09.2019.

Research output: Contribution to journalArticle

Suda, K, Shimoji, M, Shimizu, S, Sato, K, Chiba, M, Tomizawa, K, Takemoto, T, Sou, J & Mitsudomi, T 2019, 'Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas', Biomolecules, vol. 9, no. 9. https://doi.org/10.3390/biom9090456
Suda, Kenichi ; Shimoji, Masaki ; Shimizu, Shigeki ; Sato, Katsuaki ; Chiba, Masato ; Tomizawa, Kenji ; Takemoto, Toshiki ; Sou, Junichi ; Mitsudomi, Tetsuya. / Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas. In: Biomolecules. 2019 ; Vol. 9, No. 9.
@article{e40e79266a8545bc9496a5c40be57312,
title = "Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas",
abstract = "Although lung adenocarcinomas (LADs) with ground-glass opacity (GGO; part-solid tumors) have been shown to differ from those without GGO (pure-solid tumors) in clinicopathological features and prognoses, whether programmed death ligand-1 (PD-L1) protein expression differs between these two tumor types is unclear. This study included 124 patients with clinical T1a-c LAD who received pulmonary resections during 2007-2009. The E1L3N antibody was used to stain for PD-L1 in primary LAD specimens. The specimens were considered PD-L1+ if ≥1{\%} of tumor cells showed membrane staining, and were classified as having a high PD-L1+ tumor proportion score (TPS) if ≥50{\%} of the tumor cells did so. Among the 124 patients, 45 had part-solid tumors and 79 had pure-solid tumors. These two groups did not significantly differ in terms of clinical factors. However, the rates for PD-L1 positivity (4{\%} vs. 25{\%}, p < 0.01) and high PD-L1+ TPS (2{\%} vs. 16{\%}, p = 0.02) were significantly higher in the pure-solid tumors. The multivariate analyses (logistic regression model) showed that the odds ratios for PD-L1 positivity and high PD-L1+ TPS in pure-solid LADs were 5.9 (95{\%} CI; 1.2-29.7) and 8.0 (95{\%} CI; 1.0-63.8), respectively. In conclusion, LADs with GGO were correlated with a lower incidence of PD-L1 expression than pure-solid tumors.",
keywords = "biomarkers, ground-glass opacity (GGO), lung cancer, surgery",
author = "Kenichi Suda and Masaki Shimoji and Shigeki Shimizu and Katsuaki Sato and Masato Chiba and Kenji Tomizawa and Toshiki Takemoto and Junichi Sou and Tetsuya Mitsudomi",
year = "2019",
month = "9",
day = "7",
doi = "10.3390/biom9090456",
language = "English",
volume = "9",
journal = "Biomolecules",
issn = "2218-273X",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "9",

}

TY - JOUR

T1 - Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas

AU - Suda, Kenichi

AU - Shimoji, Masaki

AU - Shimizu, Shigeki

AU - Sato, Katsuaki

AU - Chiba, Masato

AU - Tomizawa, Kenji

AU - Takemoto, Toshiki

AU - Sou, Junichi

AU - Mitsudomi, Tetsuya

PY - 2019/9/7

Y1 - 2019/9/7

N2 - Although lung adenocarcinomas (LADs) with ground-glass opacity (GGO; part-solid tumors) have been shown to differ from those without GGO (pure-solid tumors) in clinicopathological features and prognoses, whether programmed death ligand-1 (PD-L1) protein expression differs between these two tumor types is unclear. This study included 124 patients with clinical T1a-c LAD who received pulmonary resections during 2007-2009. The E1L3N antibody was used to stain for PD-L1 in primary LAD specimens. The specimens were considered PD-L1+ if ≥1% of tumor cells showed membrane staining, and were classified as having a high PD-L1+ tumor proportion score (TPS) if ≥50% of the tumor cells did so. Among the 124 patients, 45 had part-solid tumors and 79 had pure-solid tumors. These two groups did not significantly differ in terms of clinical factors. However, the rates for PD-L1 positivity (4% vs. 25%, p < 0.01) and high PD-L1+ TPS (2% vs. 16%, p = 0.02) were significantly higher in the pure-solid tumors. The multivariate analyses (logistic regression model) showed that the odds ratios for PD-L1 positivity and high PD-L1+ TPS in pure-solid LADs were 5.9 (95% CI; 1.2-29.7) and 8.0 (95% CI; 1.0-63.8), respectively. In conclusion, LADs with GGO were correlated with a lower incidence of PD-L1 expression than pure-solid tumors.

AB - Although lung adenocarcinomas (LADs) with ground-glass opacity (GGO; part-solid tumors) have been shown to differ from those without GGO (pure-solid tumors) in clinicopathological features and prognoses, whether programmed death ligand-1 (PD-L1) protein expression differs between these two tumor types is unclear. This study included 124 patients with clinical T1a-c LAD who received pulmonary resections during 2007-2009. The E1L3N antibody was used to stain for PD-L1 in primary LAD specimens. The specimens were considered PD-L1+ if ≥1% of tumor cells showed membrane staining, and were classified as having a high PD-L1+ tumor proportion score (TPS) if ≥50% of the tumor cells did so. Among the 124 patients, 45 had part-solid tumors and 79 had pure-solid tumors. These two groups did not significantly differ in terms of clinical factors. However, the rates for PD-L1 positivity (4% vs. 25%, p < 0.01) and high PD-L1+ TPS (2% vs. 16%, p = 0.02) were significantly higher in the pure-solid tumors. The multivariate analyses (logistic regression model) showed that the odds ratios for PD-L1 positivity and high PD-L1+ TPS in pure-solid LADs were 5.9 (95% CI; 1.2-29.7) and 8.0 (95% CI; 1.0-63.8), respectively. In conclusion, LADs with GGO were correlated with a lower incidence of PD-L1 expression than pure-solid tumors.

KW - biomarkers

KW - ground-glass opacity (GGO)

KW - lung cancer

KW - surgery

UR - http://www.scopus.com/inward/record.url?scp=85071987230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071987230&partnerID=8YFLogxK

U2 - 10.3390/biom9090456

DO - 10.3390/biom9090456

M3 - Article

C2 - 31500267

AN - SCOPUS:85071987230

VL - 9

JO - Biomolecules

JF - Biomolecules

SN - 2218-273X

IS - 9

ER -